PRECLINICAL & TRANSLATIONAL RESEARCH
Cellular Plasticity and Cancer Group

MARÍA ABAD

MARÍA ABAD
Principal Investigator
Biosketch

STRATEGIC GOALS

  • Advance understanding of the interplay between cellular plasticity and cancer.
  • Decipher the molecular mechanisms governing the acquisition of cellular plasticity during tumorigenesis.
  • Design novel therapeutic approaches based in the inhibition of cancer cell plasticity.

CURRENT OBJECTIVES

  • Discover and characterize novel microproteins involved in cancer cell plasticity.
  • Generate new therapeutic agents and patient-stratification tools based on cancer microproteins.
  • Study the crosstalk between cellular senescence and cancer cell plasticity.

TEAM

  • Principal Investigator
    • María Abad
  • Research Assistant
    • Marta Giménez
  • Postdoctoral Fellow
    • Elena Senís
  • PhD Students
    • Olga Boix
    • Alba Escriche
    • Emanuela Greco
    • Iñaki Merino
    • Marion Martínez
  • Visiting student
    • Camilla Bertani

Publications

  • Salazar-Roa M, Trakala M, Alvarez-Fernandez M, Valdes-Mora F, Munoz J, Zapatero-Solana E, Grana O, Peters T, Abad M, Bueno M, Gomez de Cedron M, Fernandez-Piqueras J, De Martino A, Serrano M, Wang D, Clark S, Ortega S and Malumbres M. Transient exposure to miR-203 enhances the differentiation capacity of established pluripotent stem cells. In press. Embo Journal. DOI:10.15252/embj.2019104324
  • Merino I, Greco E, Abad M (2020). The microproteome of cancer: from invisibility to relevance. Experimental Cell Research. 2020;392(1):111997. doi:10.1016/j.yexcr.2020.111997
  • Senís E, Mosteiro L, Wilkening S, Wiedtke E, Nowrouzi A, Afzal S, Fronza R, Landerer H, Abad M, Niopek D, Schmidt M, Serrano M, Grimm D. AAVvector-mediated in vivo reprogramming into pluripotency. Nat Commun. 2018 Jul 9;9(1):2651. doi: 10.1038/s41467-018-05059-x.
  • Abad M, Hashimoto H, Zhou H, Morales MG, Chen B, Bassel-Duby R, Olson EN. Notch Inhibition Enhances Cardiac Reprogramming by Increasing MEF2C Transcriptional Activity. Stem Cell Reports. 2017 Mar 14;8(3):548-560.
  • Marión RM, López de Silanes I, Mosteiro L, Gamache B, Abad M, Guerra C, Megías D, Serrano M, Blasco MA. Common Telomere Changes during In Vivo Reprogramming and Early Stages of Tumorigenesis. Stem Cell Reports. 2017 Feb 14;8(2):460-475.
  • Gómez-Cabello D, Checa-Rodríguez C, Abad M, Serrano M, Huertas P. CtIP-Specific Roles during Cell Reprogramming Have Long-Term Consequences in the Survival and Fitness of Induced Pluripotent Stem Cells. Stem Cell Reports. 2017 Feb 14;8(2):432-445.
  • Mosteiro L, Pantoja C, Alcázar N, Marión RM, Chondronasiou D, Rovira M, Fernández-Marcos PJ, Muñoz M, Blanco-Aparicio C, Pastor J, Gómez-López G, de Martino A, Blasco MA, Abad M and Serrano M. Tissue damage and senescence provide critical signals for cellular reprogramming in vivo. Science. 2016 Nov 25;354(6315). pii: aaf4445.
  • Adrados I., Larrasa J., Galarreta A., López-Antona I., Menendez C., Abad M., Gil J., Moreno-Bueno G. And Palmero I. The homeoprotein SIX1 controls cellular senescence through the regulation of p16INK4A and differentiation-related genes. Oncogene. 2016 Jul 7;35(27):3485-94
  • Vilas JM, Ferreirós A, Carneiro C, Morey L, Da Silva-Álvarez S, Fernandes T, Abad M, Di Croce L, García-Caballero T, Serrano M, Rivas C, Vidal A, Collado M. Transcriptional regulation of Sox2 by the retinoblastoma family of pocket proteins. Oncotarget. 2015 Feb 20;6(5):2992-3002.
  • Palla A.R., Piazzolla D., Abad M., Li H., Dominguez O., Schönthaler H.B., Wagner E.F. and Serrano M. Reprogramming activity of NANOGP8, a NANOG family member widely expressed in cancer. Oncogene. 2014 May 8;33(19):2513-9
  • Abad M, Mosteiro L, Pantoja C, Cañamero M, Rayon T, Ors I, Graña O, Megías D, Domínguez O, Martínez D, Manzanares M, Ortega S, Serrano M. Reprogramming in vivo produces teratomas and iPS cells with totipotency features. Nature. 2013 Oct 17;502(7471):340-5.
  • Abad M, Moreno A, Palacios A, Narita M, Blanco F, Moreno-Bueno G, Narita M and Palmero I. The tumor suppressor ING1 contributes to epigenetic control of cellular senescence. Aging Cell. 2011 Feb; 10:158-71.
  • Menéndez C, Abad M, Gómez-Cabello D, Moreno A and Palmero I. ING proteins in cellular senescence. Curr Drug Targets. 2009 May;10:406-1.
  • Abad M, Menéndez C, Fuchtabuer A, Serrano M, Fuchtbauer E-M and Palmero I. Ing1 mediates p53 accumulation and chromatin modification in response to oncogenic stress. J Biol Chem. 2007 Oct 19;282:31060-7
  • Goeman F.,Thormeyer D., Abad M., Serrano M., Schmidt  O., Palmero I. and Baniahmad A.  Growth inibition by the tumor suppressor p33ING1 in immortalized and primary cells: Involvement of two silencing domains and effect of Ras. Mol Cell Biol. 2005 Jan;25:422-31.